Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of triqeminovascular activation

British Journal of Pharmacology

Volumn 157, Issue 3, 2009, Pages 464-473

  Andreou, A P ^a   Holland, P R ^a   Goadsby, P J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcitonin gene related peptide; Kainate receptors; Neurogenic dural vasodilatation

Indexed keywords

1 (2 AMINO 2 CARBOXYETHYL) 3 (2 CARBOXYBENZYL)PYRIMIDINE 2,4 DIONE; 5 IODOWILLARDIINE; CALCITONIN GENE RELATED PEPTIDE; GLUTAMATE RECEPTOR 5; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; PYRIMIDINE DERIVATIVE; UBP 302; UNCLASSIFIED DRUG; 1-(2-AMINO-2-CARBOXYETHYL)-3-(2-CARBOXYBENZYL)PYRIMIDINE-2,4-DIONE; 5-IODOWILLARDIINE; ALANINE; DRUG DERIVATIVE; GLUR5 KAINATE RECEPTOR; THYMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DURA MATER; ELECTROSTIMULATION; MALE; MENINGEAL ARTERY; MICROSCOPY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; TRIGEMINUS GANGLION; VASODILATATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY; SENSORY NERVE; SPRAGUE DAWLEY RAT; TRIGEMINAL NERVE; VASCULARIZATION;

AFFERENT PATHWAYS; ALANINE; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; DURA MATER; ELECTRIC STIMULATION; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, KAINIC ACID; THYMINE; TRIGEMINAL NERVE; VASODILATION;

EID: 61849123421     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00142.x     Document Type: Article

References (79)

1. Agrawal SG, Evans RH (1986). The primary afferent depolarizing action of kainate in the rat. Br J Pharmacol 87: 345-355. (Pubitemid 17178563)
2. Akerman S, Goadsby PJ (2005a). The role of dopamine in a model of trigeminovascular nociception. J Pharmacol Exp Ther 314: 162-169. (Pubitemid 41058252)
3. Akerman S, Goadsby PJ (2005b). Topiramate inhibits cortical spread- ing depression in rat and cat: impact in migraine aura. Neuroreport 16: 1383-1387. (Pubitemid 41225215)
4. Akerman S, Goadsby PJ (2005c). Topiramate inhibits trigeminovascu- lar activation: an intravital microscopy study. Br J Pharmacol 146: 7-14.
5. Akerman S, Williamson D, Hill RG, Goadsby PJ (2001). The effect of adrenergic compounds on neurogenic dural vasodilatation. Eur J Pharmacol 424: 53-58. (Pubitemid 32695554)
6. Akerman S, Kaube H, Goadsby PJ (2002a). Vanilloid receptor 1 (VRl) evoked CGRP release plays a minor role in causing dural vessel dilation via the trigeminovascular system. Cephalalgia 22: 572.
7. Akerman S, Williamson DJ, Kaube H, Goadsby PJ (2002b). Nitric oxide synthase inhibitors can antagonise neurogenic and calcitonin gene- related peptide induced dilation of dural meningeal vessels. Br f Pharmacol 137: 62-68. (Pubitemid 34983464)
8. Andreou AP, Storer RJ, Holland PR, Goadsby PJ (2006). CNQX inihib- its trigeminovascular neurons in the rat: a microiontophoresis study. Cephalalgia 26: 1383.
9. Andreou AP, Holland PR, Goadsby PJ (2007a). GluR5 kainate receptor activation inhibits trigeminal neurogenic dural vasodilation. Ceph- alalgia 27: 608.
10. Andreou AP, Holland PR, Goadsby PJ (2007b). Pre- and post-synaptic involvement of GluRS kainate receptors in trigeminovascular noci- ceptive processing. Cephalalgia 27: 605.
11. AuIt B, Hildebrand LM (1993). Activation of nociceptive reflexes by peripheral kainate receptors. J Pharmacol Exp Ther 265: 927-932.
12. Bardoni R, Torsney C, Tong CK, Prandini M, Macdermott AB (2004). Presynaptic NMDA receptors modulate glutamate release from primary sensory neurons in rat spinal cord dorsal horn. J Neurosci 24: 2774-2781. (Pubitemid 38380954)
13. Bergerot A, Holland PR, Akerman S, Bartsch T, Ahn AH, Maassenvan- denbrink A et al. (2006). Animal models of migraine. Looking at the component parts of a complex disorder. Eur J Neurosci 24: 1517-1534.
14. Carlton SM, Hargett GL, Coggeshall RE (1995). Localization and acti- vation of glutamate receptors in unmyelinated axons of rat glabrous skin. Neurosci Lett. 197: 25-28.
15. Carlton SM, Chung K, Ding Z, Coggeshall RE (1998). Glutamate recep- tors on postganglionic sympathetic axons. Neuroscience 83: 601-605. (Pubitemid 28062648)
16. Chan KY, Gupta S, Van Veghel R, De Vries R, Danser AHJ, Maassen Van Den Brink A (2009). Distinct effects of several glutamate receptor antagonists on rat dural artery diameter in a rat intravital micros- copy model. Cephalalgia 29: 101.
17. Classey JD, Knight YE, Goadsby PJ (2001). The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigemlnocervical complex following superior sagittal sinus stimu- lation in the cat. Brain Res 907: 117-124.
18. Coggeshall RE, Carlton SM (1998). Ultrastructural analysis of NMDA, AMPA, and kainate receptors on unmyelinated and myelinated axons in the periphery. J Comp Neurol 391: 78-86.
19. Coggeshall RE, Carlton SM (1999). Evidence for an inflammation- induced change in the local glutamatergic regulation of postgangli- onic sympathetic efferents. Pain 83: 163-168.
20. Degroot J, Zhou S, Carlton SM (2000). Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation. Neuroreport 11: 497-502. (Pubitemid 30120464)
21. Du J, Zhou S, Carlton SM (2006). Kainate-induced excitation and sensitization of nociceptors in normal and inflamed rat glabrous skin. Neuroscience 137: 999-1013. (Pubitemid 43053962)
22. Faraci FM, Breese KR, Heistad DD (1994). Responses of cerebral arte- rioles to kainate. Stroke 25: 2080-2083.
23. Filla SA, Winter MA, Johnson KW, Bleakman D, Bell MG, Bleisch TJ et al. (2002). Ethyl (3S,4aR,6S,8aK)-6-(4-ethoxycar-bonylimidazol-l- ylmethyI)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. J Med Chem 45: 4383-4386.
24. Gill S, Veinot J, Kavanagh M, Pulido O (2007). Human heart glutamate receptors - implications for toxicology, food safety, and drug dis- covery. Toxicol Pathol 35: 411-417. (Pubitemid 46453751)
25. Gill SS, Pulido OM, Mueller RW, Mcguire PF (1998). Molecular and immunochemical characterization of the ionotropic glutamate receptors in the rat heart. Brain Res Bull 46: 429-434. (Pubitemid 28401869)
26. Goadsby PJ (2005). Migraine pathophysiology. Headache 45: S14-S24.
27. Goodsby PJ, Keywood C (2009). Investigation of the role of mGluR5 inhibition in migraine: A proof of concept study of ADX10059 in acute treatment of migraine. Neurology 72 (Suppl. 1): in press.
28. Goadsby PJ, Lipton RB, Ferrari MD (2002). Migraine - current under- standing and treatment. N Engl Med 346: 257-270.
29. Headache Classification Committee of the International Headache Society (2004). The International Classification of Headache Disor- ders, 2nd edn. Cephalalgia 24: 1-160.
30. Ho T, Mannix L, Fan X, Assaid C, Furtek C, Jones C et al. (2008). Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology 70: 1004-1012. (Pubitemid 351550355)
31. Holland PR, Akerman S, Goadsby PJ (2005). Orexin 1 receptor activa- tion attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 315: 1380-1385. (Pubitemid 41635428)
32. Huettner JE (2003). Kainate receptors and synaptic transmission. Prog Neurobiol 70: 387-407.
33. Huettner JE, Kerchner GA, Zhuo M (2002). Glutamate and the presyn- aptic control of spinal sensory transmission. Neuroscientist 8: 89-92.
34. Hwang SJ, Pagliardini S, Rustioni A, Valtschanoff JG (2001). Presyn- aptic kainate receptors in primary afferents to the superficial laminae of the rat spinal cord. J Comp Neurol 436: 275-289. (Pubitemid 32613619)
35. Jane DE, Hoo K, Kamboj R, Deverill M, Bleakman D, Mandelzys A (1997). Synthesis of willardiine and 6-azawillardiine analogs: phar- macological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J Med Chem 40: 3645-3650. (Pubitemid 27465096)
36. Johnson KW, Nisenbaum ES, Johnson MP, Dieckman DK, Clemens- Smith A, Siuda ER et al. (2008). Innovative drug development for headache disorders: glutamate. In: Olesen J, Ramadan N (eds). Frontiers in Headache Research. Oxford: New York, p. 185-194.
37. Jones CK, Alt A, Ogden AM, Bleakman D, Simmons RM, Iyengar S et al. (2006). Antiallodynic and antihyperalgesic effects of selective com- petitive GLUK5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in rats. J Pharmacol Exp Ther 319: 396-404. (Pubitemid 44455147)
38. Kamiya H (2002). Kainate receptor-dependent presynaptic modula- tion and plasticity. Neurosci Res 41: 1-6.
39. Kamiya H, Ozawa S (2000). Kainate receptor-mediated presynaptic inhibition at the mouse hippocampal mossy fibre synapse. J Physiol 523: 653-665. (Pubitemid 30153825)
40. Kerchner GA, Wilding TJ, Li P, Zhuo M, Huettner JE (2001). Presyn- aptic kainate receptors regulate spinal sensory transmission. J Neurosci 21: 59-66. (Pubitemid 32098726)
41. Kinkelin I, Brocker EB, Koltzenburg M, Carlton SM (2000). Localiza- tion of ionotropic glutamate receptors in peripheral axons of human skin. Neurosci Lett 283: 149-152. (Pubitemid 30156755)
42. Knyihar-Csillik E, Toldi J, Krisztin-Peva B, Chadaide Z, Nemeth H, Fenyo R et al. (2007). Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci Lett 418: 122-126. (Pubitemid 46635993)
43. Ko S, Zhao MG, Toyoda H, Qiu CS, Zhuo M (2005). Altered behavioral responses to noxious stimuli and fear in glutamate receptor 5 (GluR5)- or GIuR6-deficient mice. J Neurosci. 25: 977-984. (Pubitemid 40171014)
44. Kurosawa M, Messlinger K, Pawlak M, Schmidt RF (1995). Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br J Pharmacol 114: 1397-1402.
45. Lee CJ, Bardoni R, Tong CK, Engelman HS, Joseph DJ, Magherini PC et al. (2002). Functional expression of AMPA receptors on central terminals of rat dorsal root ganglion neurons and presynaptic inhi- bition of glutamate release. Neuron 35: 135-146. (Pubitemid 34804328)
46. Lerma J (2003). Roles and rules of kainate receptors in synaptic trans- mission. Nat Rev Neurosci 4: 481-495.
47. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF et al. (2007). Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68: 343-349. (Pubitemid 46184209)
48. Lucifora S, Willcockson HH, Lu CR, Darstein M, Phend KD, Valtscha- noff JG et al. (2006). Presynaptic low- and high-affinity kainate receptors in nociceptive spinal afferents. Pain 120: 97-105.
49. May A, Goadsby PJ (2001). Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs 10: 1-6. (Pubitemid 32288185)
50. Mitsikostas DD, Sanchez Del Rio M, Waeber C, Moskowitz MA, Cutrer FM (1998). The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 76: 239-248. (Pubitemid 28304962)
51. Mitsikostas DD, Sanchez Del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA (1999). Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 127: 623-630.
52. More JC, Nistico R, Dolman NP, Clarke VR, Alt AJ, Ogden AM et al. (2004). Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47: 46-64. (Pubitemid 38686310)
53. Morley P, Small DL, Murray CL, Mealing GA, Poulter MO, Durkin JP et al. (1998). Evidence that functional glutamate receptors are not expressed on rat or human cerebromicrovascular endothelial cells. J Cereb Blood Flow Metab 18: 396-406. (Pubitemid 28166515)
54. Negrete-Diaz JV, Sihra TS, Delgado-Garcia JM, Rodriguez-Moreno A (2006). Kainate receptor-mediated inhibition of glutamate release involves protein kinase A in the mouse hippocampus. J Neurophysiol 96: 1829-1837.
55. Olesen J, Diener H-C, Husstedt I-W, Goadsby PJ, Hall D, Meier U et al. (2004). Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med 350: 1104-1110.
56. Paleček J, Neugebauer V, Carlton SM, Iyengar S, Willis WD (2004). The effect of a kainate GluR5 receptor antagonist on responses of spinothalamic tract neurons in a model of peripheral neuropathy in primates. Pain 111: 151-161. (Pubitemid 39141017)
57. Peeters M, Gunthorpe MJ, Strijbos PJ, Goldsmith P, Upton N, James MF (2007). Effects of pan- and subtype-selective N-Methyl-D- aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther 321: 564-572. (Pubitemid 46624518)
58. Porter RH, Jaeschke G, Spooren W, Ballard TM, Buttelmann B, Kolc- zewski S et al. (2005). Fenobam: a clinically validated nonbenzodi- azepine anxiolytic is a potent, selective, and noncompetitive mGluS receptor antagonist with inverse agonist activity. J Pharma- col Exp Ther 315: 711-721.
59. Robinson JS, Fedinec AL, Leffler CW (2002). Role of carbon monoxide in glutamate receptor-Induced dilation of newborn pig pial arteri- oles. Am J Physiol Heart Circ Physiol 282: H2371-H2376.
60. Rodriguez-Moreno A, Sihra TS (2004). Presynaptic kainate receptor facilitation of glutamate release involves protein kinase A in the rat hippocampus. J Physiol 557: 733-745. (Pubitemid 38961612)
61. Ruscheweyh R, Sandkuhler J (2002). Role of kainate receptors in noci- ception. Brain Res Rev 40: 215-222. (Pubitemid 36183170)
62. Sahara Y, Noro N, lida Y, Soma K, Nakamura Y (1997). Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci 17: 6611-6620.
63. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR et al. (2004). LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24: 596-602.
64. 1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36: 525-533.
65. Simmons RM, Li DL, Hoo KH, Deverill M, Ornstein PL, Iyengar S (1998). Kainate GluR5 receptor subtype mediates the nocicep- tive response to formalin in the rat. Neuropharmacology 37: 25-36. (Pubitemid 28300135)
66. St'astny F, Schwendt M, Lisy V, Jezova D (2002). Main subunits of ionotropic glutamate receptors are expressed in isolated rat brain microvessels. Neurol Res 24: 93-96.
67. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003). The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Ceph- alalgia 23: 519-527. (Pubitemid 37114973)
68. Storer RJ, Goadsby PJ (1999). Trigeminovascular nociceptive transmis- sion involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 90: 1371-1376.
69. Swanson GT, Green T, Heinemann SF (1998). Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol Phar- macol 53: 942-949. (Pubitemid 28244083)
70. Turner MS, Hamamoto DT, Hodges JS, Maccecchini ML, Simone DA (2003). SYM 2081, an agonist that desensitizes kainate receptors, attenuates capsaicin and inflammatory hyperalgesia. Brain Res 973: 252-264.
71. Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A etal. (2006). Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther 318: 772-781.
72. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997a). Intra- vital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia 17: 518-524.
73. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997b). Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 17: 525-531.
74. Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ (1997c). The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 328: 61-64.
75. 1H/1D agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 133: 1029-1034.
76. Wolff HG (1948). Headache and Other Head. Pain. Oxford University Press: New York.
77. Wong LA, Mayer ML, Jane DE, Watkins JC (1994). Willardiines differ- entiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons. J Neurosci 14: 3881-3897. (Pubitemid 24174131)
78. Wu DC, Zhou N, Yu LC (2003). Anti-nociceptive effect induced by intrathecal injection of ATPA, an effect enhanced and prolonged by concanavalin A. Brain Res 959: 275-279. (Pubitemid 35472189)
79. Xiao Y, Richter JA, Hurley JH (2008). Release of glutamate and CGRP from trigeminal ganglion neurons: role of calcium channels and 5-HT1 receptor signaling. Mol Pain 4: 12. (Pubitemid 351622384)